Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs.

× No keyword cloud information.

12 in total

1. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Authors: Nazzareno Cervelli; Giuliano Tocci; Claudio Ferri
Journal: High Blood Press Cardiovasc Prev Date: 2018-01-05

2. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.

Authors: Paul L Hess; Kevin Kennedy; Michael Cowherd; Salim S Virani; Frederick A Masoudi; Ann Marie Navar; Robert W Yeh; P Michael Ho; Thomas M Maddox
Journal: Am Heart J Date: 2017-09-09 Impact factor: 4.749

Review 3. Appropriate Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Atherosclerotic Cardiovascular Disease: Comparison of Recommendations from Different Guidelines or Consensus Around the World.

Authors: Jia-Ling Lin; Po-Hsun Huang; Hung-I Yeh; Yi-Heng Li
Journal: Acta Cardiol Sin Date: 2020-09 Impact factor: 2.672

4. Application of PCSK9 Inhibitors in Practice.

Authors: Tina M Kaufman; Bruce A Warden; Jessica Minnier; Joshua R Miles; P Barton Duell; Jonathan Q Purnell; Cezary Wojcik; Sergio Fazio; Michael D Shapiro
Journal: Circ Res Date: 2019-01-04 Impact factor: 17.367

5. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.

Authors: Christopher P Cannon; Irfan Khan; Alexa C Klimchak; Matthew R Reynolds; Robert J Sanchez; William J Sasiela
Journal: JAMA Cardiol Date: 2017-09-01 Impact factor: 14.676

6. Just Price for PCSK9 Inhibitors: No less, No More.

Authors: Khurram Nasir
Journal: J Am Heart Assoc Date: 2018-11-06 Impact factor: 5.501

7. Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study.

Authors: Dennis T Ko; Anam M Khan; Gynter Kotrri; Peter C Austin; Harindra C Wijeysundera; Maria Koh; Anna Chu; Cynthia A Jackevicius; Patrick R Lawler; Jack V Tu
Journal: J Am Heart Assoc Date: 2018-11-06 Impact factor: 5.501

8. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis.

Authors: Peter P Toth; Craig Granowitz; Michael Hull; Amy Anderson; Sephy Philip
Journal: Lipids Health Dis Date: 2019-09-16 Impact factor: 3.876

9. Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-17.

Authors: Ali Allahyari; Tomas Jernberg; Dominik Lautsch; Pia Lundman; Emil Hagström; Jessica Schubert; Robert Boggs; Stina Salomonsson; Peter Ueda
Journal: Eur Heart J Qual Care Clin Outcomes Date: 2021-01-25

Review 10. Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations.

Authors: David I Feldman; Erin D Michos; Neil J Stone; Ty J Gluckman; Miguel Cainzos-Achirica; Salim S Virani; Roger S Blumenthal
Journal: Am J Prev Cardiol Date: 2020-11-13